Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

Summary

GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.

Timeline

Start

2006-05

Primary completion

2007-10

Completion

2007-10

Outcome

Outcome not reported

Stopped (Enrollment): “Study cancelled before enrollment”

Drugs

Indications